Downregulation of the Arg/N-degron Pathway Sensitizes Cancer Cells to Chemotherapy In Vivo
DownloadPublished version (3.012Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
© 2020 The American Society of Gene and Cell Therapy With the use of a small interfering RNA (siRNA)-mediated approach for selective downregulation of the Arg/N-degron pathway in a murine hepatocellular carcinoma model, Leboeuf et al. demonstrated potentiated action of chemotherapy. Since components of this pathway are ubiquitously expressed, targeting the N-degron pathway has the potential to increase effectiveness of therapy in many cancer types.
Date issued
2020-01Department
Koch Institute for Integrative Cancer Research at MIT; Massachusetts Institute of Technology. Department of Chemical Engineering; Harvard University--MIT Division of Health Sciences and Technology; Massachusetts Institute of Technology. Institute for Medical Engineering & ScienceJournal
Molecular Therapy
Publisher
Elsevier BV
ISSN
1525-0024